Linked Life Data

21062978

Source:http://linkedlifedata.com/resource/pubmed/id/21062978

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
22
pubmed:dateCreated
2010-11-16
pubmed:abstractText
The objective of this study was to assess the relationship of the tumor protein levels of TOP2A and MIB-1 and ERG status with cancer-specific outcomes in men with high-risk prostate cancer treated by radical prostatectomy (RP). A 150-pair case-control study was designed from RP patients who developed systemic progression (SP) within 6 years of RP (cases) and men who were free of disease at least 8 years after RP (controls). The cases and controls were matched on conventional prognostic clinical parameters. TOP2A and MIB-1 levels were assessed by immunohistochemical methods, and ERG status was assessed by quantitative reverse transcription-PCR. The prognostic abilities of TOP2A and MIB-1 were significantly better in ERG(-) patients, and TOP2A was superior to MIB-1. In receiver operating characteristic analysis, the TOP2A and MIB-1 scores exhibited AUCs of 0.81 and 0.78 for ERG(-) patients, versus 0.67 and 0.68 for ERG(+) patients, respectively. Clinical parameters attained an AUC of 0.65 in ERG(-) patients and 0.54 in ERG(+) patients. When both markers were incorporated into a model for ERG(-) patients, the AUC increased to 0.83, with TOP2A showing a stronger association with SP than MIB-1. The time to SP was significantly associated with TOP2A; higher 5-year SP rates were observed in patients with higher TOP2A protein levels. In addition, although patient numbers are small, the response to adjuvant androgen deprivation therapy is associated with ERG status, showing more significant treatment effect in ERG(+) patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1538-7445
pubmed:author
pubmed:copyrightInfo
Copyright © 2010 AACR.
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
70
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
8994-9002
pubmed:meshHeading
pubmed-meshheading:21062978-Aged, pubmed-meshheading:21062978-Antigens, Neoplasm, pubmed-meshheading:21062978-Case-Control Studies, pubmed-meshheading:21062978-DNA Topoisomerases, Type II, pubmed-meshheading:21062978-DNA-Binding Proteins, pubmed-meshheading:21062978-Disease Progression, pubmed-meshheading:21062978-Gene Expression Regulation, Neoplastic, pubmed-meshheading:21062978-Humans, pubmed-meshheading:21062978-Immunohistochemistry, pubmed-meshheading:21062978-Ki-67 Antigen, pubmed-meshheading:21062978-Male, pubmed-meshheading:21062978-Middle Aged, pubmed-meshheading:21062978-Multivariate Analysis, pubmed-meshheading:21062978-Neoplasm Staging, pubmed-meshheading:21062978-Prognosis, pubmed-meshheading:21062978-Prostate-Specific Antigen, pubmed-meshheading:21062978-Prostatectomy, pubmed-meshheading:21062978-Prostatic Neoplasms, pubmed-meshheading:21062978-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:21062978-Risk Factors, pubmed-meshheading:21062978-Survival Analysis, pubmed-meshheading:21062978-Time Factors, pubmed-meshheading:21062978-Trans-Activators, pubmed-meshheading:21062978-Tumor Markers, Biological
pubmed:year
2010
pubmed:articleTitle
The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status.
pubmed:affiliation
Department of Urology, Laboratory Medicine and Pathology, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA. karnes.r@mayo.edu
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural